Adiponectin and Insulin Resistance in Diabetic Nephropathy

This study has been completed.
Shanghai Jiao Tong University School of Medicine
Information provided by:
Xi’an Jiaotong University College of Medicine Identifier:
First received: October 16, 2008
Last updated: October 17, 2008
Last verified: October 2008
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).

Condition Intervention
Diabetic Nephropathy
Drug: Losartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan

Resource links provided by NLM:

Further study details as provided by Xi’an Jiaotong University College of Medicine:

Primary Outcome Measures:
  • GFR, HbA1c and the adiponectin concentration [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Enrollment: 80
Study Start Date: April 2007
Study Completion Date: November 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Losartan
    Angiotensin II Type 1 Receptor Blockers

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetic nephropathy
  • CKD at stage 1~4

Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00774904

Shanghai No.3 people's hospital
Shanghai, China, 201900
Sponsors and Collaborators
Xi’an Jiaotong University College of Medicine
Shanghai Jiao Tong University School of Medicine
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: hui min Jin, shanghai No 3 people's hospital Identifier: NCT00774904     History of Changes
Other Study ID Numbers: ADPN 
Study First Received: October 16, 2008
Last Updated: October 17, 2008
Health Authority: China: Food and Drug Administration

Keywords provided by Xi’an Jiaotong University College of Medicine:
Type 2 Diabetes
Diabetic Nephropathy
Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers

Additional relevant MeSH terms:
Diabetic Nephropathies
Insulin Resistance
Kidney Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Urologic Diseases
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 30, 2016